LYCOS RETRIEVER 
Celebrex: Pains
built 645 days ago
Celebrex, generic drug name celecoxib, is the only COX-2 selective NSAID currently on the market in the United States. COX-2 selective NSAIDs are a subset of a broader group of nonsteroidal anti-inflammatory drugs used to reduce arthritis pain, inflammation, and stiffness. Celebrex was approved by the U.S. FDA on December 31, 1998.
Source:
Pfizer Chief Executive Officer Hank McKinnel said as recently as December 6, 2004 that there was no evidence Celebrex was dangerous. Celebrex was believed to be a safer alternative to Vioxx, and in the months since Vioxx was recalled Celebrex sales have jumped. In the first full month of data after the Vioxx recall, in October 2004, sales of Celebrex topped $260 million, or 63.5 percent of the market for COX-2 inhibitors, according to IMS Health. In September 2004, Celebrex had accounted for 48.7 percent of the market for new generation painkillers.
Source:
Celebrex, a prescription medication that belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs), is frequently used for acute pain, arthritis, and painful menstrual periods. It works by blocking the COX-2 enzyme, which plays a role in pain and inflammation. The medication comes in capsule form and is available in several strengths. The most common side effects of Celebrex are indigestion, diarrhea, and abdominal pain.
Source:
Celebrex is a COX-2 inhibitor NSAID. Exactly how it works is not known. It might block confident substances in the body that are linked to inflammation. NSAIDs treat the symptoms of pain as well as inflammation. They do not treat the disease that causes those symptoms.
Source:
Celebrex is approved for use in the United States for the treatment of arthritis and pain, at recommended doses of 100mg to 200mg daily for osteoarthritis and 200mg to 400mg a day for rheumatoid arthritis. It is ... approved for a rare condition called familial adenomatous polyposis in doses up to 800mg per day. The APC cancer trial studied Celebrex at doses of 400mg to 800mg per day. In the PreSAP cancer trial the dose was 400mg per day.
Source:
Celebrex and Vioxx were introduced to the U.S. market in 1999 as arthritis painkillers. Both drugs, alongside Bextra, are part of a class of drugs called COX-2 inhibitors that were immediately popular when emerging onto the market.
Source:
MORE ABOUT
Pains